PneuVUE®: A new view into Pneumonia among adults 65 years and over

As we age, our immune system generally declines in reliability and efficiency, resulting in an increased susceptibility to infectious diseases[1]. As such, the 65 years and over age-group is also at increased risk for pneumococcal disease[2].

Following the successful publication of the PneuVUE®: A New View into Pneumonia Among Older Adults report focusing on those aged 50 years and over, Ipsos MORI conducted a data sub-analysis focusing on respondents aged 65 years and over - a group at increased risk of pneumonia[2].

The sub-analysis informed the PneuVUE®: 65 Years and Over report, which looks at the respondents’ awareness of and attitudes towards pneumonia and pneumonia vaccination* within the context of our globally ageing population, as well as the changing face of this age-group, relative to attitudes and behaviour around health, lifestyle and work.

Key findings:

  • Whilst the majority (85%) of adults aged 65 years and over claim to know what pneumonia is, only a-third (35%) know that there is a pneumonia vaccination*
  • Only 18% of the 65 years and over age group reported having received a pneumonia vaccination* compared to 48% reporting regularly (defined as at least 4 times in the past 5 years) having had a flu vaccination
  • 42% of the 65 years and over who had not received a pneumonia vaccination* believe there are better ways to protect against it.

PneuVUE® (Adult Pneumonia Vaccination* Understanding in Europe) is one of the largest pneumonia awareness surveys ever conducted in Europe (across nine European countries) and is based on over 9,000 interviews among people aged 50 years and over. A total of 4,441 participated were aged 65 years and over, which formed the basis for the sub-analysis. The interviews were conducted by telephone between November 2015 and February 2016. The PneuVUE® survey, sponsored by Pfizer Vaccines** and backed by independent leading experts, shows that across Europe, there is a generally poor understanding about the risks and prevention of pneumonia.

Quotas*** were imposed to ensure national representation based on age, gender, region and employment status. Corrective weights have been applied to bring the sample in line with the population profile per country and population size in each of the nine countries.

≠All references to pneumonia within the PneuVUE® survey are to all-cause pneumonia, not pneumococcal pneumonia specifically

*The PneuVUE® survey questioned respondents regarding pneumonia as a whole. Pneumococcal vaccination can only protect against pneumonia caused by the pneumococcal serotypes contained in the vaccine

**Pfizer International Operations, RCS 491 295 671 Paris, France

***Quotas were based on 2011 Eurostat census data

References

[1]Caruso C, Buffa S, Candore G et al. Mechanisms of immunosenescence. Immunity and Ageing. 200-: 6:10

[2]Shea KM et al. Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions. Open Forum Infect Dis. 2014 May 27; 1(1). Available at: https://www.ncbi.nlm.nih.gov/pubmed?term=((shea%5BAuthor%5D)%20AND%20pneumonia)%20AND%2065 [Last accessed: 10 August 2017].

 

More insights about Health

Society